TIL Therapy: Lessons Learned and Potential Future Directions in CareFebruary 23rd 2023
Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.
Data from Additional Clinical Studies on Tumor-Infiltrating Lymphocyte TherapyFebruary 16th 2023
Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.
An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid TumorsFebruary 3rd 2023
Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.